TORONTO, Canada - Celestica Inc. (NYSE, TSX: CLS), a global leader in the delivery of end-to-end product lifecycle solutions, today announced the company's growing healthcare segment "Celestica HealthTech" has formed an Advisory Council to provide critical guidance as the company continues to focus on helping healthcare OEMs accelerate their success.
Celestica's appointed Advisory Council members each possess deep experience and expertise in healthcare technology innovation, product lifecycle and supply chain management, market globalization, regulatory trends and healthcare reform. The following executives have been appointed to the Advisory Council:
Dr. David Goodman, MD, MSE, currently serves on the Board of Directors of NEUROMetrix (Nasdaq: NURO), a neurotechnology company focused on the early detection of diabetic peripheral neuropathy (DPN) and treatment of painful diabetic neuropathy (PDN). He also serves as a director of Sound Surgical Technologies LLC, a private manufacturer of aesthetic surgical tools. Trained in both biomedical engineering and medicine, Dr. Goodman began his career as the first engineer at Nellcor, the company that developed modern pulse oximetry. Dr. Goodman holds a B.A.S. in applied science and bioengineering and a M.S.E. in bioengineering from the University of Pennsylvania. He received an M.D. cum laude from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology. He holds 18 US patents and is licensed to practice medicine in California.
Dr. Eric Maurincomme, PhD, is currently Chief Executive Officer, INSA Lyon, France, one of the top international engineering universities in Europe and Chairman of the Board at Insavalor, its research and technology transfer subsidiary. He is the former Chief Strategy and Marketing Officer at Agfa Healthcare in Belgium. Previously, Dr. Maurincomme spent 10 years at GE Healthcare as a senior business leader of neurovascular and cardiac imaging product lines. He is an expert in the area of Imaging and eHealth and served over many years as the Healthcare IT Committee Chairman for the European industry organization COCIR, and as Governing Council Member of HIMSS Europe.
Christopher Van Ingen is Chairman of the Board of Bruker Energy & Superconducting Technologies Inc.; Director of the Bruker Corporation; Chairman of the Board at Accelrys, Inc; Director of Senova Systems, Inc.; and Director of Promega Corporation. Mr. Van Ingen specializes in life science and analytical instrumentation. He was President of Agilent Technologies' Bio-Analytical Measurement Group from 2001 to 2007. Prior to that, he had a long career at Hewlett Packard and was Vice President of Sales and Marketing for their Chemical Analysis Group from 1996 to 2001.
The main function of the Advisory Council is to provide valuable market insight and generate actionable strategic input for Celestica as the company develops new and innovative supply chain solutions, designed specifically for the healthcare industry.
"Today's announcement reflects Celestica's commitment to providing our customers with the people, knowledge and innovative solutions to help them drive competitive advantage in this dynamic industry," said Sandra Ketchen, Vice President, Celestica HealthTech. "We will leverage the Council's deep insight and expertise in medical device technology to ensure we are best positioned to help our customers as they strive to improve patient care around the globe."
Celestica HealthTech provides design, automated manufacturing, electronics manufacturing, fulfillment and after-market services to medical equipment companies. The company operates a network of facilities that are ISO 9001/13485 certified and FDA QSR compliant. Four of these sites are US FDA-registered manufacturers of medical devices.
Celestica is dedicated to delivering end-to-end product lifecycle solutions to drive our customers' success. Through our simplified global operations network and information technology platform, we are solid partners who deliver informed, flexible solutions that enable our customers to succeed in the markets they serve. Committed to providing a truly differentiated customer experience, our agile and adaptive employees share a proud history of demonstrated expertise and creativity that provides our customers with the ability to overcome any challenge.
Celestica HealthTech works with medical device companies to help them bring innovative technologies to market faster and more efficiently. We collaborate with our customers to improve patient care through innovative thinking and advanced technical expertise. Our manufacturing, supply chain and after-market solutions accelerate product development and rapid delivery of quality healthcare technology.
Celestica Safe Harbour and Fair Disclosure Statement
Statements contained in this press release which are not historical facts are forward-looking statements. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions, or may employ such future or conditional verbs as "may", "will", "should," or "would," or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and in any applicable Canadian securities legislation. Forward looking statements are not guarantees of future performance. Risks and uncertainties, as well as other information related to the Company, are discussed in the Company's various public filings at www.sedar.com and www.sec.gov, including our Annual Report on Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission and our Annual Information Form filed with the Canadian Securities Commissions. Forward-looking statements are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.